Literature DB >> 16378780

Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey.

Bartolome R Celli1, R J Halbert, Robert J Nordyke, Brigitte Schau.   

Abstract

PURPOSE: Chronic obstructive pulmonary disease (COPD) is usually described as a disease of cigarette smoking. COPD is rarely considered in persons with no smoking history except in the context of another exposure. Accordingly, the disease has not been well characterized in these "never smokers."
METHODS: We evaluated airway obstruction (defined as forced expiratory volume in 1 second/forced vital capacity <0.70) in US adults aged 30 to 80 years interviewed in the Third National Health and Nutrition Examination Survey with valid spirometry who had never smoked. Previously described risk factors were examined for their association with obstruction in bivariate and multivariate analyses.
RESULTS: Never smokers represented 42% of the Third National Health and Nutrition Examination Survey population aged 30 to 80 years, with obstruction prevalence of 91 per 1000. Never smokers accounted for 4.56 million cases of obstruction, or 23% of the total burden. Among these obstructed never smokers, 19% reported a prior diagnosis of asthma alone, and 12.5% reported COPD (alone or with asthma), leaving 68.5% with no prior respiratory diagnosis. After adjustment for other factors, higher rates of obstruction were significantly associated with increasing age, male sex, lower body mass index, and a history of allergies.
CONCLUSIONS: Never smokers represent a significant proportion of airway obstruction in US adults. Only one fifth of obstruction in this group is explained by asthma. COPD may explain much of the remainder, although known risk factors were not explanatory in this dataset. Recommendations that lung health screening programs be limited to smokers should be reconsidered.

Entities:  

Mesh:

Year:  2005        PMID: 16378780     DOI: 10.1016/j.amjmed.2005.06.041

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  50 in total

1.  Low Vitamin D Status Is Associated with Inflammation in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Lin Fu; Jun Fei; Zhu-Xia Tan; Yuan-Hua Chen; Biao Hu; Hui-Xiang Xiang; Hui Zhao; De-Xiang Xu
Journal:  J Immunol       Date:  2020-12-23       Impact factor: 5.422

2.  Validity of chronic obstructive pulmonary disease diagnoses in a large administrative database.

Authors:  Yves Lacasse; Jean-Marc Daigle; Sylvie Martin; François Maltais
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

3.  The efficacy and safety of cilomilast in COPD. Forward.

Authors:  Alvar Agusti
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.

Authors:  Sara M May; James T C Li
Journal:  Allergy Asthma Proc       Date:  2015 Jan-Feb       Impact factor: 2.587

5.  Comment on: Wollmer P, Engström G. Fixed ratio or lower limit of normal (LLN) as cut-off value for FEV1/VC: An outcome study. Respiratory Medicine (2013) 107, 1460-1462.: Fixed ratio or lower limit of normal (LLN) as cut-off value for FEV1/VC.

Authors:  Carlos A Vaz Fragoso; Jeffrey J Pretto; Philip H Quanjer
Journal:  Respir Med       Date:  2015-05-02       Impact factor: 3.415

6.  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era.

Authors:  Matthew R Gingo; M Patricia George; Cathy J Kessinger; Lorrie Lucht; Barbara Rissler; Renee Weinman; William A Slivka; Deborah K McMahon; Sally E Wenzel; Frank C Sciurba; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

7.  Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Thomas M Gill
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

8.  Exposure to PM10 as a risk factor for the development of nasal obstruction and chronic obstructive pulmonary disease.

Authors:  Lazaros Sichletidis; Dionisios Spyratos; Anastasios Tsiotsios; Anna-Bettina Haidich; Ioannis Ganidis; Dimitrios Michailidis; Georgios Triantafyllou; George Kottakis; Dimitrios Melas
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

9.  The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill
Journal:  Am J Respir Crit Care Med       Date:  2009-12-17       Impact factor: 21.405

10.  Assessment of patients with chronic obstructive pulmonary disease.

Authors:  Barry J Make; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.